Baird analyst Colleen Kusy raised the firm’s price target on Ocular Therapeutix (OCUL) to $24 from $17 and keeps an Outperform rating on the shares. The firm updated its model following the company’s investor day.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Buy Rating for Ocular Therapeutix Driven by Strategic Advancements and Promising Clinical Trials in Diabetic Retinopathy
- Ocular Therapeutix: Buy Rating Affirmed Amid Promising Clinical Advancements and Strong Financial Position
- Ocular Therapeutix price target raised to $29 from $20 at Citizens JMP
- Ocular Therapeutix’s Strategic Initiatives and Clinical Advancements Drive Buy Rating
- Ocular Therapeutix Announces $475M Stock Offering